Loading…
Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
Introduction The purpose of the current study is to compare definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with cT1-3/N0-3 esophageal squamous cell carcinoma in survival. Methods Records from 2008 to 2014 of 4931 patients with clinical T1-3/N0-3 esophageal...
Saved in:
Published in: | PloS one 2022-01, Vol.17 (10) |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | |
container_issue | 10 |
container_start_page | |
container_title | PloS one |
container_volume | 17 |
creator | Yi-Lin Chang Ya-Fu Cheng Hui-Shan Chen Siao-Chi Wu Wei-Heng Hung Heng-Chung Chen Chang-Lun Huang Ching-Yuan Cheng Bing-Yen Wang |
description | Introduction The purpose of the current study is to compare definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with cT1-3/N0-3 esophageal squamous cell carcinoma in survival. Methods Records from 2008 to 2014 of 4931 patients with clinical T1-3/N0-3 esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or esophagectomy with adjuvant chemoradiotherapy were obtained from the Taiwan Cancer Registry. Univariable and multivariable analyses were performed and propensity score matching was used to minimize the bias. Overall survival was compared between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy, and also in the three different clinical stages. Results Definitive chemoradiotherapy was performed on 4381 patients, and 550 patients received esophagectomy adjuvant chemoradiotherapy. Each group produced 456 patients for comparison after propensity score matching. The 1-year, 2-year, and 3-year overall survival rates for matched patients in with definitive chemoradiotherapy group were 57.18%, 31.92%, and 23.8%. The 1-year, 2-year, and 3-year overall survival rates for matched patients treated in the esophagectomy with adjuvant chemoradiotherapy group were 72.35%, 45.74%, and 34.04%(p |
format | article |
fullrecord | <record><control><sourceid>doaj</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b</doaj_id><sourcerecordid>oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b</sourcerecordid><originalsourceid>FETCH-doaj_primary_oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b3</originalsourceid><addsrcrecordid>eNqtjklOxTAQRCMkJD7DHfoCX3IGDFkjEOxYsI86difpyBO2k6-cjOsRMexYsiqpVK-qzopD2dbVUVaiviguU5qFuK3vpTwUH6_RB3KJ8wZJ-UiADs2WOIHyNmBkN0Ja4sorGugpn4gcaBrYceaVQE1kfUTNPk8UMWx7gQZKPkw4ksrebnDiPAHqeVnR5T8IdhAwM7mcvrO_-D6Z3he0ftnvkDGgMCp23uJ1cT6gSXTzo1fFy9Pj28PzUXucuxDZYtw6j9x9GT6OHcbMylCnVKPLVlJLom1UKfqq6fFOyrIVwyBFX_9n1yfVmYJN</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Yi-Lin Chang ; Ya-Fu Cheng ; Hui-Shan Chen ; Siao-Chi Wu ; Wei-Heng Hung ; Heng-Chung Chen ; Chang-Lun Huang ; Ching-Yuan Cheng ; Bing-Yen Wang</creator><creatorcontrib>Yi-Lin Chang ; Ya-Fu Cheng ; Hui-Shan Chen ; Siao-Chi Wu ; Wei-Heng Hung ; Heng-Chung Chen ; Chang-Lun Huang ; Ching-Yuan Cheng ; Bing-Yen Wang</creatorcontrib><description>Introduction The purpose of the current study is to compare definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with cT1-3/N0-3 esophageal squamous cell carcinoma in survival. Methods Records from 2008 to 2014 of 4931 patients with clinical T1-3/N0-3 esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or esophagectomy with adjuvant chemoradiotherapy were obtained from the Taiwan Cancer Registry. Univariable and multivariable analyses were performed and propensity score matching was used to minimize the bias. Overall survival was compared between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy, and also in the three different clinical stages. Results Definitive chemoradiotherapy was performed on 4381 patients, and 550 patients received esophagectomy adjuvant chemoradiotherapy. Each group produced 456 patients for comparison after propensity score matching. The 1-year, 2-year, and 3-year overall survival rates for matched patients in with definitive chemoradiotherapy group were 57.18%, 31.92%, and 23.8%. The 1-year, 2-year, and 3-year overall survival rates for matched patients treated in the esophagectomy with adjuvant chemoradiotherapy group were 72.35%, 45.74%, and 34.04%(p<0.0001). In multivariable analysis, treatment modality was an independent prognostic factor. Esophagectomy with adjuvant chemoradiotherapy provided better survival outcome than definitive chemoradiotherapy for patients with clinical stage II/III disease. As for patients with clinical stage I disease, there was no significant survival difference between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy. Conclusions Esophagectomy with adjuvant chemoradiotherapy provided better survival than definitive chemoradiotherapy in clinical II/III esophageal squamous cell carcinoma. However, more data are needed to conduct a convincing conclusion in clinical stage I patients.</description><identifier>EISSN: 1932-6203</identifier><language>eng</language><publisher>Public Library of Science (PLoS)</publisher><ispartof>PloS one, 2022-01, Vol.17 (10)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Yi-Lin Chang</creatorcontrib><creatorcontrib>Ya-Fu Cheng</creatorcontrib><creatorcontrib>Hui-Shan Chen</creatorcontrib><creatorcontrib>Siao-Chi Wu</creatorcontrib><creatorcontrib>Wei-Heng Hung</creatorcontrib><creatorcontrib>Heng-Chung Chen</creatorcontrib><creatorcontrib>Chang-Lun Huang</creatorcontrib><creatorcontrib>Ching-Yuan Cheng</creatorcontrib><creatorcontrib>Bing-Yen Wang</creatorcontrib><title>Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma</title><title>PloS one</title><description>Introduction The purpose of the current study is to compare definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with cT1-3/N0-3 esophageal squamous cell carcinoma in survival. Methods Records from 2008 to 2014 of 4931 patients with clinical T1-3/N0-3 esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or esophagectomy with adjuvant chemoradiotherapy were obtained from the Taiwan Cancer Registry. Univariable and multivariable analyses were performed and propensity score matching was used to minimize the bias. Overall survival was compared between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy, and also in the three different clinical stages. Results Definitive chemoradiotherapy was performed on 4381 patients, and 550 patients received esophagectomy adjuvant chemoradiotherapy. Each group produced 456 patients for comparison after propensity score matching. The 1-year, 2-year, and 3-year overall survival rates for matched patients in with definitive chemoradiotherapy group were 57.18%, 31.92%, and 23.8%. The 1-year, 2-year, and 3-year overall survival rates for matched patients treated in the esophagectomy with adjuvant chemoradiotherapy group were 72.35%, 45.74%, and 34.04%(p<0.0001). In multivariable analysis, treatment modality was an independent prognostic factor. Esophagectomy with adjuvant chemoradiotherapy provided better survival outcome than definitive chemoradiotherapy for patients with clinical stage II/III disease. As for patients with clinical stage I disease, there was no significant survival difference between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy. Conclusions Esophagectomy with adjuvant chemoradiotherapy provided better survival than definitive chemoradiotherapy in clinical II/III esophageal squamous cell carcinoma. However, more data are needed to conduct a convincing conclusion in clinical stage I patients.</description><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqtjklOxTAQRCMkJD7DHfoCX3IGDFkjEOxYsI86difpyBO2k6-cjOsRMexYsiqpVK-qzopD2dbVUVaiviguU5qFuK3vpTwUH6_RB3KJ8wZJ-UiADs2WOIHyNmBkN0Ja4sorGugpn4gcaBrYceaVQE1kfUTNPk8UMWx7gQZKPkw4ksrebnDiPAHqeVnR5T8IdhAwM7mcvrO_-D6Z3he0ftnvkDGgMCp23uJ1cT6gSXTzo1fFy9Pj28PzUXucuxDZYtw6j9x9GT6OHcbMylCnVKPLVlJLom1UKfqq6fFOyrIVwyBFX_9n1yfVmYJN</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Yi-Lin Chang</creator><creator>Ya-Fu Cheng</creator><creator>Hui-Shan Chen</creator><creator>Siao-Chi Wu</creator><creator>Wei-Heng Hung</creator><creator>Heng-Chung Chen</creator><creator>Chang-Lun Huang</creator><creator>Ching-Yuan Cheng</creator><creator>Bing-Yen Wang</creator><general>Public Library of Science (PLoS)</general><scope>DOA</scope></search><sort><creationdate>20220101</creationdate><title>Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma</title><author>Yi-Lin Chang ; Ya-Fu Cheng ; Hui-Shan Chen ; Siao-Chi Wu ; Wei-Heng Hung ; Heng-Chung Chen ; Chang-Lun Huang ; Ching-Yuan Cheng ; Bing-Yen Wang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-doaj_primary_oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yi-Lin Chang</creatorcontrib><creatorcontrib>Ya-Fu Cheng</creatorcontrib><creatorcontrib>Hui-Shan Chen</creatorcontrib><creatorcontrib>Siao-Chi Wu</creatorcontrib><creatorcontrib>Wei-Heng Hung</creatorcontrib><creatorcontrib>Heng-Chung Chen</creatorcontrib><creatorcontrib>Chang-Lun Huang</creatorcontrib><creatorcontrib>Ching-Yuan Cheng</creatorcontrib><creatorcontrib>Bing-Yen Wang</creatorcontrib><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yi-Lin Chang</au><au>Ya-Fu Cheng</au><au>Hui-Shan Chen</au><au>Siao-Chi Wu</au><au>Wei-Heng Hung</au><au>Heng-Chung Chen</au><au>Chang-Lun Huang</au><au>Ching-Yuan Cheng</au><au>Bing-Yen Wang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma</atitle><jtitle>PloS one</jtitle><date>2022-01-01</date><risdate>2022</risdate><volume>17</volume><issue>10</issue><eissn>1932-6203</eissn><abstract>Introduction The purpose of the current study is to compare definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with cT1-3/N0-3 esophageal squamous cell carcinoma in survival. Methods Records from 2008 to 2014 of 4931 patients with clinical T1-3/N0-3 esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or esophagectomy with adjuvant chemoradiotherapy were obtained from the Taiwan Cancer Registry. Univariable and multivariable analyses were performed and propensity score matching was used to minimize the bias. Overall survival was compared between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy, and also in the three different clinical stages. Results Definitive chemoradiotherapy was performed on 4381 patients, and 550 patients received esophagectomy adjuvant chemoradiotherapy. Each group produced 456 patients for comparison after propensity score matching. The 1-year, 2-year, and 3-year overall survival rates for matched patients in with definitive chemoradiotherapy group were 57.18%, 31.92%, and 23.8%. The 1-year, 2-year, and 3-year overall survival rates for matched patients treated in the esophagectomy with adjuvant chemoradiotherapy group were 72.35%, 45.74%, and 34.04%(p<0.0001). In multivariable analysis, treatment modality was an independent prognostic factor. Esophagectomy with adjuvant chemoradiotherapy provided better survival outcome than definitive chemoradiotherapy for patients with clinical stage II/III disease. As for patients with clinical stage I disease, there was no significant survival difference between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy. Conclusions Esophagectomy with adjuvant chemoradiotherapy provided better survival than definitive chemoradiotherapy in clinical II/III esophageal squamous cell carcinoma. However, more data are needed to conduct a convincing conclusion in clinical stage I patients.</abstract><pub>Public Library of Science (PLoS)</pub><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1932-6203 |
ispartof | PloS one, 2022-01, Vol.17 (10) |
issn | 1932-6203 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b |
source | Open Access: PubMed Central; Publicly Available Content Database |
title | Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A54%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Propensity%20score%20analysis%20comparing%20survival%20between%20definitive%20chemoradiotherapy%20and%20esophagectomy%20with%20adjuvant%20chemoradiotherapy%20in%20patients%20with%20esophageal%20squamous%20cell%20carcinoma&rft.jtitle=PloS%20one&rft.au=Yi-Lin%20Chang&rft.date=2022-01-01&rft.volume=17&rft.issue=10&rft.eissn=1932-6203&rft_id=info:doi/&rft_dat=%3Cdoaj%3Eoai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b%3C/doaj%3E%3Cgrp_id%3Ecdi_FETCH-doaj_primary_oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |